Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method.
Lung cancer
Lung-RADS
deep machine learning
ensemble learning
screening
survival analysis
time-dependent ROC
volume doubling time
Journal
The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
entrez:
1
9
2020
pubmed:
31
8
2020
medline:
31
8
2020
Statut:
ppublish
Résumé
Current lung cancer screening guidelines use mean diameter, volume or density of the largest lung nodule in the prior computed tomography (CT) or appearance of new nodule to determine the timing of the next CT. We aimed at developing a more accurate screening protocol by estimating the 3-year lung cancer risk after two screening CTs using deep machine learning (ML) of radiologist CT reading and other universally available clinical information. A deep machine learning (ML) algorithm was developed from 25,097 participants who had received at least two CT screenings up to two years apart in the National Lung Screening Trial. Double-blinded validation was performed using 2,294 participants from the Pan-Canadian Early Detection of Lung Cancer Study (PanCan). Performance of ML score to inform lung cancer incidence was compared with Lung-RADS and volume doubling time using time-dependent ROC analysis. Exploratory analysis was performed to identify individuals with aggressive cancers and higher mortality rates. In the PanCan validation cohort, ML showed excellent discrimination with a 1-, 2- and 3-year time-dependent AUC values for cancer diagnosis of 0·968±0·013, 0·946±0·013 and 0·899±0·017. Although high ML score cohort included only 10% of the PanCan sample, it identified 94%, 85%, and 71% of incident and interval lung cancers diagnosed within 1, 2, and 3 years, respectively, after the second screening CT. Furthermore, individuals with high ML score had significantly higher mortality rates (HR=16·07, p<0·001) compared to those with lower risk. ML tool that recognizes patterns in both temporal and spatial changes as well as synergy among changes in nodule and non-nodule features may be used to accurately guide clinical management after the next scheduled repeat screening CT.
Sections du résumé
Background
Current lung cancer screening guidelines use mean diameter, volume or density of the largest lung nodule in the prior computed tomography (CT) or appearance of new nodule to determine the timing of the next CT. We aimed at developing a more accurate screening protocol by estimating the 3-year lung cancer risk after two screening CTs using deep machine learning (ML) of radiologist CT reading and other universally available clinical information.
Methods
A deep machine learning (ML) algorithm was developed from 25,097 participants who had received at least two CT screenings up to two years apart in the National Lung Screening Trial. Double-blinded validation was performed using 2,294 participants from the Pan-Canadian Early Detection of Lung Cancer Study (PanCan). Performance of ML score to inform lung cancer incidence was compared with Lung-RADS and volume doubling time using time-dependent ROC analysis. Exploratory analysis was performed to identify individuals with aggressive cancers and higher mortality rates.
Findings
In the PanCan validation cohort, ML showed excellent discrimination with a 1-, 2- and 3-year time-dependent AUC values for cancer diagnosis of 0·968±0·013, 0·946±0·013 and 0·899±0·017. Although high ML score cohort included only 10% of the PanCan sample, it identified 94%, 85%, and 71% of incident and interval lung cancers diagnosed within 1, 2, and 3 years, respectively, after the second screening CT. Furthermore, individuals with high ML score had significantly higher mortality rates (HR=16·07, p<0·001) compared to those with lower risk.
Interpretation
ML tool that recognizes patterns in both temporal and spatial changes as well as synergy among changes in nodule and non-nodule features may be used to accurately guide clinical management after the next scheduled repeat screening CT.
Identifiants
pubmed: 32864596
doi: 10.1016/S2589-7500(19)30159-1
pmc: PMC7450858
mid: NIHMS1545878
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Pagination
e353-e362Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Lancet Oncol. 2017 Nov;18(11):1523-1531
pubmed: 29055736
Nat Med. 2019 Jun;25(6):954-961
pubmed: 31110349
Cancer Imaging. 2010 Jul 06;10:137-43
pubmed: 20605762
Cancer Med. 2018 Dec;7(12):6340-6356
pubmed: 30507033
Sci Rep. 2017 Apr 19;7:46479
pubmed: 28422152
Thorax. 2015 Aug;70 Suppl 2:ii1-ii54
pubmed: 26082159
Stat Med. 1995 Jan 15;14(1):73-82
pubmed: 7701159
Med Image Anal. 2017 Dec;42:60-88
pubmed: 28778026
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
Ann Intern Med. 2015 Apr 7;162(7):485-91
pubmed: 25664444
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
N Engl J Med. 2013 Feb 21;368(8):728-36
pubmed: 23425165
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Radiol Phys Technol. 2017 Mar;10(1):23-32
pubmed: 28211015
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
Onco Targets Ther. 2015 Aug 04;8:2015-22
pubmed: 26346558
N Engl J Med. 2013 Sep 5;369(10):910-9
pubmed: 24004118
PLoS One. 2018 May 14;13(5):e0196910
pubmed: 29758038
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Radiology. 2018 Jan;286(1):286-295
pubmed: 28872442
J Med Imaging (Bellingham). 2018 Jan;5(1):011021
pubmed: 29594181
AJR Am J Roentgenol. 2017 Nov;209(5):1009-1014
pubmed: 28898131
Int J Biomed Imaging. 2013;2013:942353
pubmed: 23431282
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441
pubmed: 29632061